Currency In USD
| Previous Close | 1.29 |
| Open | 1.29 |
| Day High | 1.37 |
| Day Low | 1.26 |
| 52-Week High | 5.55 |
| 52-Week Low | 1.26 |
| Volume | 137,664 |
| Average Volume | 150,619 |
| Market Cap | 5.55M |
| PE | -0.34 |
| EPS | -3.83 |
| Moving Average 50 Days | 1.54 |
| Moving Average 200 Days | 2.53 |
| Change | 0.03 |
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
GlobeNewswire Inc.
Feb 05, 2026 1:05 PM GMT
Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the company Phase 3 Study enrollment remains ahead of s
IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
GlobeNewswire Inc.
Dec 30, 2025 1:30 PM GMT
LAWRENCEVILLE, N.J., Dec. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has entered into a securities purchase agreement with a
IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026
GlobeNewswire Inc.
Dec 29, 2025 4:10 PM GMT
Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces IMNN-001's Promise as a Potential Breakthrough Immunotherapy LAWRENCEVILLE, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- IMUNO